Shandong Xinhua Pharmaceutical (HKG:0719, SHE:000756) reported a net profit attributable to the shareholders of 344.1 million yuan for the first nine months of the year, a decrease of 12.2% compared with 392.0 million yuan a year ago.
Earnings per share were 0.50 yuan, down from 0.57 yuan in the year-ago period, according to a Tuesday filing with the Hong Kong Stock Exchange.
The company's gross revenue stood at 6.73 billion yuan, a 3.6% increase compared with 6.50 billion yuan a year earlier.
The company's Hong Kong-listed shares were down 3% in the recent trading, while its Chinese shares were down 2%.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments